MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period. Instrument revenue of $15.3 million compared with $35.1 million in the prior-year... Read more
Q4 2024 revenues of $979.6 million, up 14.6% year-over-year (yoy); Bruker organic revenue up 3.9%, and constant-exchange rate (CER) revenue up 15.8%; Bruker Scientific Instrument (BSI) segment organic revenue up 4.5% Q4 2024 non-GAAP operating margin of 18.1%, as operational excellence and integration initiatives fully offset strategic M&A and FX operating margin headwinds Q4 2024... Read more
Bruker Announces Date and Time of Fourth Quarter 2024 Earnings Release and Webcast BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before market opening on Thursday, February 13, 2025. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard... Read more
Company leads value chain partners in purchase agreement that adds 118 megawatts (MW) of solar energy to enable decarbonization across the pharmaceutical and healthcare industries WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a 10-year virtual power purchasing agreement (VPPA) with international renewable energy developer X-ELIO... Read more
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company’s new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences... Read more
WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter revenue grew 5% to $11.40 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew... Read more
WASHINGTON, Jan. 29, 2025 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion, or $1.49 per diluted common share and non-GAAP adjusted diluted... Read more
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics. The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying... Read more
UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support... Read more
Danaher Announces Investment Partnership in Innovaccer Inc. Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions. Investment aligns with Danaher’s mission to accelerate the transition to precision medicine with AI-enabled diagnostics. WASHINGTON, Jan. 9, 2025 /PRNewswire/ — Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (NYSE:... Read more